Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Toleranzia AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Toleranzia | 75 | GlobeNewswire (Europe) | The Swedish Companies Registration Office (Sw. Bolagsverket) has granted permission to Flerie AB (publ) ("Flerie") to carry out the merger plan concerning the merger between Flerie and Toleranzia AB... ► Artikel lesen | |
31.07. | Flerie AB: The Board of Directors of Flerie has resolved to redeem all Series C shares within the framework of Flerie's share redemption scheme | 75 | GlobeNewswire (Europe) | At an Extraordinary General Meeting of Flerie AB (publ) ("Flerie" or the "Company") held on 10 June 2024, a resolution was passed to introduce a redemption scheme for the Company's shares. Redemption... ► Artikel lesen | |
FLERIE Aktie jetzt für 0€ handeln | |||||
31.07. | Flerie AB: Flerie AB (publ) Interim Report January - June 2025 | 76 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 4,121 million (4,380) and net asset value per share was SEK 52.78 (SEK 56.10 at 30 June 2024). Change in net asset value per share in the quarter was 4.4 per... ► Artikel lesen | |
16.07. | Flerie AB: Flerie AB's subsidiary Flerie Invest AB announces final outcome of the mandatory cash offer to the shareholders of Nanologica AB (publ) | 306 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
25.06. | Toleranzia AB: Toleranzia applies for delisting of the Company's shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie | 81 | GlobeNewswire (Europe) | Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25... ► Artikel lesen | |
13.06. | Nanologica AB: Statement From The Board Of Directors Of Nanologica AB (publ) Regarding The Mandatory Bid From Flerie Invest Ab | 389 | GlobeNewswire (Europe) | The Board of Directors of Nanologica AB (publ) ("Nanologica" or the "Company") unanimously recommends the shareholders of Nanologica not to accept the mandatory cash offer made by Flerie Invest AB ("Flerie")... ► Artikel lesen | |
12.06. | Flerie AB: Flerie's portfolio company Nanologica has received its first U.S. order | 557 | GlobeNewswire (Europe) | Stockholm, Sweden, June 12, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media, NLAB Saga®, from a new... ► Artikel lesen | |
03.06. | Flerie AB: Flerie's portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer | 81 | GlobeNewswire (Europe) | Stockholm, Sweden, June 3, 2025. Flerie AB's (publ) portfolio company KAHR Bio has communicated that they have presented positive Phase II results at the 2025 ASCO Annual Meeting.
The results indicate... ► Artikel lesen | |
23.05. | Nanologica AB: Comment from the Board of Nanologica AB (publ) Regarding the Mandatory Bid from Flerie Invest AB | 714 | GlobeNewswire (Europe) | Nanologica AB's (publ) ("Nanologica") main owner Flerie Invest AB ("Flerie") has today, May 23, 2025, made a mandatory cash offer of SEK 1.00 per share to the shareholders of Nanologica (the "Offer").... ► Artikel lesen | |
23.05. | Flerie AB: Flerie Invest AB announces a mandatory cash offer to the shareholders of Nanologica AB (publ) | 709 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO ANY JURISDICTION (INCLUDING WITHOUT LIMITATION AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE... ► Artikel lesen | |
14.05. | Flerie AB: The General Meetings of Flerie and Toleranzia respectively have approved the merger plan and the General Meeting in Flerie has resolved on issuance of the merger consideration | 91 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
30.04. | Flerie AB: Flerie receives FDI-approval for the merger with Toleranzia | 238 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
26.04. | Nanologica AB: Nanologica AB Informs that Flerie Invest AB has Passed the Threshold for Mandatory Bid | 662 | GlobeNewswire (Europe) | Nanologica's main owner Flerie Invest AB ("Flerie") has acquired additional shares in Nanologica AB with the result that a mandatory bid obligation has arisen. Flerie's total holding in Nanologica after... ► Artikel lesen | |
22.04. | LIPUM AB: Lipum looks ahead to phase II with backing from Flerie | 3 | Cision News | ||
16.04. | Flerie AB: Flerie AB Interim Report January - March 2025 | 138 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,947 million (3,416) and net asset value per share was SEK 50.56 (56.24), adjusted net asset value per share was 51.88 (56.24). Change in net asset value... ► Artikel lesen | |
14.04. | Flerie AB: Flerie's portfolio company Lipum presents positive results from its Phase I trial with SOL-116 | 160 | GlobeNewswire (Europe) | Stockholm, Sweden, April 14, 2025. Flerie AB announces that its portfolio company Lipum has presented final results from a Phase I trial evaluating SOL-116 in healthy volunteers and patients with rheumatoid... ► Artikel lesen | |
25.03. | Toleranzia AB: Statement by the Board of Directors of Toleranzia in view of the merger offer by Flerie | 160 | GlobeNewswire (Europe) | The Board of Directors of Toleranzia AB (publ) ("Toleranzia") unanimously recommends the shareholders of Toleranzia to vote in favour of the completion of the merger between Toleranzia and Flerie AB... ► Artikel lesen | |
25.03. | Toleranzia AB: Flerie and Toleranzia have agreed on a merger plan to take Toleranzia private | 157 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEELAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
24.03. | Nanologica AB: Nanologica AB Extends Existing Loan from Flerie | 990 | GlobeNewswire (Europe) | Nanologica has extended the existing loan from Flerie Invest AB. The end date for the loan has been extended to July 2, 2027 from previous July 5, 2025.
The loan will be paid off in stages according... ► Artikel lesen | |
22.01. | Flerie AB: Year-end report 2024 | 210 | GlobeNewswire (Europe) | October - December 2024Net asset value was SEK 4,198 million (3,566) and net asset value per share was SEK 53.77 (58.71), adjusted net asset value per share was 55.09 (58.71)Change in net asset value... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
HAEMATO | 10,100 | 0,00 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 9,350 | +1,59 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments | - Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician... ► Artikel lesen | |
PHOTOCURE | 5,050 | -0,39 % | Photocure ASA: Results for the second quarter of 2025 | OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million)... ► Artikel lesen | |
BAYER | 26,705 | +2,87 % | DAX-Check LIVE: Bayer, Commerzbank, Klöckner & Co, Kontron, Schaeffler, Siemens Energy, Vonovia | Nach einem zwischenzeitlichen Anstieg bis knapp an die 24.000-Punkte-Marke hat der DAX am Dienstag letztlich nur leicht zugelegt. Der deutsche Leitindex schloss 0,37% höher bei 23.846 Punkten. Am Nachmittag... ► Artikel lesen | |
NOVO NORDISK | 43,085 | +1,00 % | Dieses Biotech-Unternehmen schlägt Bayer, Evotec, Novo Nordisk & Co. um Längen! | Während Anlegerinnen und Anleger verzweifelt auf einen Turnaround der Aktien von Bayer, Evotec und Novo Nordisk warten, liefert dieser Rivale konstant Gewinne. Anstatt auf Verlierer sollten Anlegerinnen... ► Artikel lesen | |
MERCK KGAA | 110,05 | -0,90 % | Aktie von Merck büßt 1,42 Prozent ein (104,05 €) | Im Minus liegt zur Stunde der Anteilsschein von Merck . Der jüngste Kurs betrug 104,05 Euro. Ein Minus von 1,42 Prozent steht gegenwärtig für die Aktie von Merck zu Buche. Das Papier verbilligte sich... ► Artikel lesen | |
ELI LILLY | 553,50 | +1,04 % | Eli Lilly: Fokus auf die heutigen Quartalsergebnisse | Das US-Pharmaunternehmen Eli Lilly notiert derzeit weit von den eigenen Höchstständen entfernt. Die Aktie bewegt sich seit Wochen unterhalb der 200-Tage-Linie und signalisiert damit eine anhaltende... ► Artikel lesen | |
HARROW | 34,835 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Second-Quarter 2025 Financial Results | Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA... ► Artikel lesen | |
METSERA | 30,860 | 0,00 % | Metsera, Inc.: Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress | MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog)... ► Artikel lesen | |
CANOPY GROWTH | 1,358 | +1,34 % | Märkte am Morgen: Bitcoin, Thyssen, Cancom, Glencore, Expedia, Under Armour, Canopy, BYD/Tesla | Der DAX hat sich am Freitag mit leichten Verlusten ins Wochenende verabschiedet. Trotzdem hat der deutsche Leitindex eine starke Woche hinter sich. Unter dem Strich ging es fast 3,2 Prozent nach oben.Auch... ► Artikel lesen | |
GSK | 16,545 | +1,44 % | BERNSTEIN RESEARCH stuft GSK auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für GSK von 2290 auf 2170 Pence gesenkt, die Einstufung aber auf "Outperform" belassen. Anleger des britischen Pharmakonzerns... ► Artikel lesen | |
TILRAY BRANDS | 0,840 | +3,40 % | Tilray Brands: +40% in einer Woche nach Kauftipp! | Erst letzte Woche habe ich dargelegt, weshalb ich die Aktie von Tilray Brands wieder für kaufenswert halte. Jetzt folgt mit politischem Rückenwind ein langersehnter Kurstreiber. Allein heute legt der... ► Artikel lesen | |
PFIZER | 21,095 | -0,05 % | Pfizer-Aktie: Gut und günstig | Nach einer längeren Schwächephase scheint Pfizer die Wende zu schaffen. Das Unternehmen, das stark von der Corona-Pandemie profitierte, überzeugt nun mit starken Quartalszahlen - und zeigt klare Signale... ► Artikel lesen | |
MERCK & CO | 68,80 | 0,00 % | unverschaemt - unter den Finalisten des MSD Gesundheitspreises 2025 | Bochum (ots) - Das Bochumer Vorzeigeprojekt für sexuelle Gesundheit von KNAPPSCHAFT und WIR ist nominiert für den MSD Gesundheitspreis. Und alle können abstimmen für den Publikumspreis.Die Zahl sexuell... ► Artikel lesen | |
ROCHE | 262,20 | +0,11 % | Aktien Europa Schluss: Durchwachsene Entwicklung - Börse Zürich unter Druck | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die wichtigsten Aktienmärkte Europas haben sich am Mittwoch uneinheitlich entwickelt. Der Leitindex der Eurozone, der EuroStoxx 50, gewann 0,26 Prozent auf 5.263,29... ► Artikel lesen |